For patients and clinicians weighing the trade-offs of adding immunotherapy to standard treatment in limited-stage small cell lung cancer, quality-of-life data matter as much as survival curves. When a treatment offers no survival advantage, the question becomes whether it at least spares patients from additional burden — or imposes one. The PRO findings from NRG-LU005 now answer that directly.
This planned secondary analysis from the NRG-LU005 phase III randomized trial enrolled 544 patients with limited-stage small cell lung cancer across four arms defined by the presence or absence of atezolizumab (a PD-L1 checkpoint inhibitor) and by radiation fractionation schedule — twice-daily (BID) at 45 Gy versus once-daily (QD) at 66 Gy. Patient-reported outcomes were collected using the FACT-TOI, EQ-5D-5L utility index, and PROMIS-Fatigue at multiple time points through 24 months. The primary PRO hypothesis — that atezolizumab would reduce clinically meaningful decline in FACT-TOI at 15 months — was not met. No statistically significant difference in quality of life was detected between immunotherapy and control arms at that landmark, nor in fatigue or health utility scores at any point. A marginal signal favoring atezolizumab appeared at 21 months but warrants cautious interpretation given attrition. Notably, BID radiation was consistently associated with better patient-reported functional outcomes than QD radiation across all timepoints.
These findings complement the trial's negative survival endpoint and effectively close the door on a rationale for adding concurrent atezolizumab to chemoradiation in this setting — neither efficacy nor tolerability supports it. The BID radiation finding is particularly thought-provoking: despite delivering radiation twice daily, patients reported better functional status, reinforcing prior survival signals from the same trial and challenging the assumption that more intensive fractionation worsens experience. Limitations include PRO compliance dropping to 60–68% by later timepoints, introducing potential responder bias. Overall, this is a confirmatory and clinically important null result that should directly influence treatment decision-making.